uniQure Appoints Dan Soland as Chief Executive Officer
December 18 2015 - 6:30AM
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today
announced the appointment of Dan Soland as the new Chief Executive
Officer of the Company. Mr. Soland will succeed Jörn Aldag, who has
decided to step down as CEO, a role he has held since
2009. Mr. Soland will also be nominated for appointment to
uniQure's Management Board, subject to approval by the Company's
General Meeting of Shareholders. Mr. Aldag will be available
to assist the Company during the transition.
Mr. Soland, 57, brings to uniQure more than 30 years of industry
experience, most recently serving as Vice President and Chief
Operating Officer of ViroPharma. At ViroPharma, Mr. Soland was
responsible for building the company's organization and commercial
infrastructure until its successful sale to Shire in 2014 for
approximately $4 billion. Mr. Soland was previously President of
Chiron Vaccines, where he helped engineer a turnaround that
contributed to Chiron's acquisition by Novartis. Earlier, he was
President and CEO of Epigenesis Pharmaceuticals and Vice President
and Director of Worldwide Marketing Operations at GlaxoSmithKline
Biologicals and held positions of increasing responsibility at
Pasteur-Merieux's Connaught Laboratories (now Sanofi Pasteur). Mr.
Soland holds a B.S. in Pharmacy from the University of Iowa.
"Dan's appointment comes at an important time in the evolution
and growth of uniQure," commented Will Lewis, Chairman of uniQure's
Nomination and Governance Committee who led the search on behalf of
the Supervisory Board. "He brings significant operational
experience and knowledge of drug development that will be critical
as uniQure's pipeline advances into later-stage clinical
studies. I am confident that Dan's track record of generating
shareholder value will enable uniQure to achieve the potential that
we all believe is inherent in uniQure's broad pipeline and leading
gene therapy technology platform."
"The Supervisory Board thanks Jörn for the leadership, energy
and commitment that he has brought to uniQure since 2009. Without
his significant contributions and leadership, uniQure would not
have achieved its successes over the past six years," continued Mr.
Lewis.
"uniQure presents an exciting opportunity and I very much look
forward to collaborating with the team on both sides of the
Atlantic to advance our innovative portfolio of gene therapy
candidates to patients," commented Mr. Soland.
About uniQure
uniQure is delivering on the promise of gene therapy – single
treatments with potentially curative results. We are leveraging our
modular and validated technology platform to rapidly advance a
pipeline of proprietary and partnered gene therapies to treat
patients with CNS, liver/metabolic and cardiovascular diseases.
www.uniQure.com.
CONTACT: uniQure:
Matthew Kapusta
Chief Financial Officer
Direct: +1 339 970-7005
m.kapusta@uniqure.com
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494 or +1 781 235 3060
gschweitzer@macbiocom.com
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jul 2023 to Jul 2024